Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05437380
Collaborator
(none)
70
1
1
48
1.5

Study Details

Study Description

Brief Summary

Head and neck squamous cell carcinoma is the sixth most common malignant tumor in the world. Cervical lymph node metastasis is frequently encounted on the date of diagnosis. Surgical resection is one of the most important treatment methods for head and neck squamous cell carcinoma with or without lymph node metastasis. At present, for cN0 patients, prophylactic neck dissection is recommended for squamous cell carcinoma originating in suprglottic, hypopharyngeal and oropharyngeal areas et al. Related studies reported that less than 30% of patients with cN0 were confirmed to have lymph node metastasis in postoperative pathological examination, who underwent neck dissection. Unnecessary neck dissection may increase complication incidence, such as neurovascular injury, chylous leakage, sialosyrinx. Accurate preoperative assessment is helpful to reduce unnecessary neck dissection. Sentinel lymph node biopsy were proved to be effective in reducing prophylactic lymph node dissection in breast cancer, melanoma and other malignant tumors. Compared with γ probe detection and indolyanine green injection, microbubble and contrast-enhanced ultrasound has no radiation and disturbance to resection margins in sentinel lymph nodes detection. Furthermore, surgeons could conduct lymph node puncture biopsy simultaneously under ultrasound guidance, which can further minimize surgical trauma. At present, the role of microbubble and contrast-enhanced ultrasound in sentinel lymph node detection and biopsy is rarely reported in head and neck squamous cell carcinoma. This study aims to explore the accuracy of peritumoral microbubbles and contrast-enhanced ultrasound for sentinel lymph nodes biopsy in predicting cervical lymph node metastasis in head and neck squamous cell carcinoma.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: peritumoral microbubbles and contrast-enhanced ultrasonography
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
The Value of Peritumoral Microbubbles and Contrast-enhanced Ultrasonography to Detect and Biopsy Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
Anticipated Study Start Date :
Jun 28, 2022
Anticipated Primary Completion Date :
Jun 28, 2025
Anticipated Study Completion Date :
Jun 28, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: CEUS

Diagnostic Test: peritumoral microbubbles and contrast-enhanced ultrasonography
Inject 1ml microbubbles around the tumors. Then detect lymph vessel and lymph nodes under contrast-enhanced ultrasonography.

Outcome Measures

Primary Outcome Measures

  1. diagnostic accuracy [4 years]

    diagnostic accuracy=(true positive+true negative)/(true positive+true negative+false positive+false negative)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged 18-70;

  • Pathological biopsy indicated head and neck squamous cell carcinoma;

  • MR/CT examination indicate no suspected cervical lymph node metastasis;

  • The patient intent to perform primary focal resection and unilateral/bilateral neck dissection at our center;

  • agree to participate in clinical trials and sign informed consent.

Exclusion Criteria:
  • allergic to microbubbles contrast agents;

  • patients who cannot tolerate surgery;

  • enlarged cervical lymph node in palpation or suspected cervical lymph node metastasis indicated in MR/CT examination;

  • distant metastasis.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sun Yat-sen Memorial Hospital Guangzhou Guangdong China 510000

Sponsors and Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Investigators

  • Principal Investigator: Huang Xiaoming, M.D., Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
ClinicalTrials.gov Identifier:
NCT05437380
Other Study ID Numbers:
  • SYSKY-2022-019-02
First Posted:
Jun 29, 2022
Last Update Posted:
Jun 29, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 29, 2022